Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation.
Animals
Antineoplastic Agents
/ pharmacology
Binding, Competitive
Fluorine Radioisotopes
Hep G2 Cells
/ drug effects
Humans
Male
Mice
Mice, Nude
Neoplasm Transplantation
Positron-Emission Tomography
/ methods
Proto-Oncogene Proteins c-mdm2
/ antagonists & inhibitors
Pyrrolidines
/ pharmacology
para-Aminobenzoates
/ pharmacology
AMG232
MDM2
PET
RG7388
SJSA-1
fluorine-18
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
04 10 2021
04 10 2021
Historique:
pubmed:
16
9
2021
medline:
19
2
2022
entrez:
15
9
2021
Statut:
ppublish
Résumé
RG7388 (Idasanutlin) is a potent inhibitor of oncoprotein murine double minute 2 (MDM2). Herein we investigated the feasibility of developing
Identifiants
pubmed: 34523337
doi: 10.1021/acs.molpharmaceut.1c00531
pmc: PMC8775362
mid: NIHMS1768068
doi:
Substances chimiques
Antineoplastic Agents
0
Fluorine Radioisotopes
0
Pyrrolidines
0
RG7388
0
para-Aminobenzoates
0
Proto-Oncogene Proteins c-mdm2
EC 2.3.2.27
Fluorine-18
GZ5I74KB8G
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3871-3881Subventions
Organisme : NCI NIH HHS
ID : R21 CA241823
Pays : United States
Références
J Clin Invest. 2010 Jan;120(1):290-302
pubmed: 19955655
Sci Rep. 2017 May 11;7(1):1763
pubmed: 28496125
Science. 2004 Feb 6;303(5659):844-8
pubmed: 14704432
J Med Chem. 2013 Jul 25;56(14):5979-83
pubmed: 23808545
Invest New Drugs. 2020 Jun;38(3):831-843
pubmed: 31359240
J Med Chem. 2006 Jun 15;49(12):3432-5
pubmed: 16759082
Bioconjug Chem. 2018 Jun 20;29(6):2100-2106
pubmed: 29851469
Int J Mol Sci. 2021 Jan 25;22(3):
pubmed: 33504051
Int J Mol Sci. 2020 Sep 24;21(19):
pubmed: 32987693
Am J Surg Pathol. 2007 Oct;31(10):1476-89
pubmed: 17895748
Angew Chem Int Ed Engl. 2018 Jul 20;57(30):9284-9289
pubmed: 29768700
Curr Cancer Drug Targets. 2005 Feb;5(1):27-41
pubmed: 15720187
Chem Sci. 2019 May 30;10(26):6457-6466
pubmed: 31316744
Clin Cancer Res. 2016 Feb 15;22(4):868-76
pubmed: 26459177
Br J Cancer. 2014 Aug 12;111(4):716-25
pubmed: 24921920
Nat Commun. 2014 Oct 01;5:5086
pubmed: 25271708
Cancer Res. 1993 May 15;53(10 Suppl):2231-4
pubmed: 8387391
J Med Chem. 2014 Feb 27;57(4):1454-72
pubmed: 24456472
Cancer Res. 2014 Dec 15;74(24):7161-7
pubmed: 25477334
Cancer Res. 1993 Jun 15;53(12):2736-9
pubmed: 8504413
Cancer Res. 2019 Jan 1;79(1):251-262
pubmed: 30385614
J Med Chem. 2014 Dec 26;57(24):10499-511
pubmed: 25384157
Cancer Chemother Pharmacol. 2019 Jul;84(1):93-103
pubmed: 31062077
Genes Dis. 2019 Jun 19;6(4):419-430
pubmed: 31832522
Appl Immunohistochem Mol Morphol. 2017 Nov/Dec;25(10):712-719
pubmed: 27028243
Haematologica. 2016 May;101(5):e185-8
pubmed: 26869629
Oncogene. 1997 Aug 28;15(9):1001-10
pubmed: 9285554
PLoS One. 2014 Nov 25;9(11):e113939
pubmed: 25423279
Cancer Lett. 2017 Feb 28;387:25-31
pubmed: 27195912
Sci Rep. 2018 Jan 17;8(1):967
pubmed: 29343829
Pharmaceuticals (Basel). 2021 Apr 13;14(4):
pubmed: 33924734